Member Info for JCampz97

Although i was hoping for fireworks on the share price by now, i do remember it being stated 'a 16 week trial takes longer than 16 weeks' based on collecting and analyzing the data.

All we can really do now is hold out until the chairman's corner which will likely be released next week.

Exactly that HBD there has always been some sort of hints that we are in discussions and enabling the phase 2 package was a key part of that so Im hoping that we are ticking all of the required box's to allow a larger firm to get involved whether it be partner or even a potential buy out

Fair bit on the AI developments but the most important part

'Beyond the neuroscience programme, our priorities across the portfolio remain unchanged. The Phase 2-enabling toxicology work for SDC-1801 continues to progress, and we are advancing business development discussions around our pipeline of assets.'

Cant ask for much more really im quite pleased with this update, will just need to hold out untill completion and hope some real value comes of the business development discussions

Has anyone asked the question on does the previous research facility have to pay us a penalty / compensation / or at least refund us for our money spent on a trial that had to be abandoned ?

I understand it may not be as clear cut and require a investigation but i don't see why its just water under the bridge that we wasted so much time and money here.

This is the news we were expecting I'm not sure why it has been received so negatively

For once it is within the time frame given of Q1 perhaps the board have learned to add some tolerance to dates given in case things slip.

hopefully it is the same for the future milestones and they are all hit well within the time frame given.

Annoyingly i don't expect anything to happen for a few months now so will be ignoring any day to day swings and rumors on here until the milestones are hit in the expected outlined time frames

GSK shares have taken a dip after U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep a good read below pretty much sums up that they are running out of patent on their HIV portfolio and need newer drug approvals to help offset declining sales.

https://www.reuters.com/sustainability/boards-policy-regulation/gsk-falls-blood-cancer-drug-likely-headed-us-rejection-2025-07-18/

This could add some pressure to strike a deal with Sareum

So John and Tim according to the linked in post are able to give an update on SDC-1801 at the event while we are still waiting to hear anything on the expected 'further data, unblinded from drug/placebo recipients, including details of any mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, will be available in Q3 2024.'

over due RNS if they have the results

Yesterday the below all done write ups on Tim's step aside, i don't usually see this coverage on developments in the company from that many publishers

AJ Bell

Tipranks

Business Cloud

Research Tree

Morning Star

Just re-iterating what was already in the RNS nothing new but it could stand out to people that know how to read in between the lines of a public clinical stage bio tech company having a re-shuffle at board level

Another top up hoping that's the last negative headline for the company and this will be a bargain.

Be fearful when others are greedy & be greedy when others are fearful

Seems a great deal if you were in the know and this announcement was going to be made today.

'Keep in mind this Retail Offer will close no later than 10am on Tuesday 2 April 2024 and may close earlier'

Why would there be such a short time frame to allow current investors to purchase shares if they need the money so badly

I don't see anything worth getting excited about until we hit atleast £3 New money but it is nice to see some rise in the SP after being dragged for so long

I am under no illusion that we are still down a fair bit from previous highs and for no significant reason at all, however a recovery is good to see after such a bleak period.
Hopefully this now consecutively raises the sp like back in June when it was 25% a day all week.

As someone who doesn't follow Sierra's pipeline of development does anybody know if their latest therapy drug has any link to CHK1 or does it have zero relevancy ?

Without blaming every negative trend on MM has there been any actual negative news to warrant the recent drop ?
it was only the end of the year when another HNWI invested over £1.6m and Toxicology reports are expected to be published early 2022 so is there something I have missed ?

Interesting how dramatically perceptions of the company's future shifted in a matter of days but it was a good opportunity to top up. Hoping for as many gains as possible but i imagine it will float between 5-6.5p now until there is any actual news

Has there been any previous link of involvement with Merck ?
Even if not the fact a covid pill is coming to market could open paths for our own the same way there are several vaccines on the market